Hyderabad, Oct. 21 -- Dr. Reddy's Laboratories has received approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab), in combination with cisplatin and paclitaxel, for the first-line treatment of adults with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (ESCC).
The approval marks the drug's second approved indication in India, following its earlier approval for nasopharyngeal carcinoma, the Hyderabad based pharma giant said in a press release on Wednesday.
The approved treatment does not require patient selection based on PD-L1 expression, allowing eligible patients to be considered for therapy regardless of their biomarker status.
The approval is supported by findings from...